"Promising Results: Melanoma Vaccine Shows Long-Term Benefits and Potential for Commercial Success"

Moderna's experimental vaccine against melanoma, the most serious form of skin cancer, could be available in as little as two years, according to CEO Stephane Bancel. The vaccine, which uses messenger RNA technology, has shown promising results in clinical trials, reducing the risk of recurrence or death by 49 percent over a three-year period. Moderna is seeking accelerated approval for the vaccine, which is tailored to each patient's specific tumor mutations. The company is also developing vaccines for other types of tumors and hopes to pair them with early detection tests for better efficacy. Other companies, such as BioNTech, are also working on individualized therapeutic cancer vaccines.